Patent Application
20150223770
This invention relates to the field of medicine, for the diagnosis of osteoporosis and measurement of the effectiveness of therapeutic and prophylactic treatment of conditions associated with osteoporosis.
Osteoporosis (hereinafter referred to as OP) is a metabolic skeletal disease, characterised by decreased bone mass per unit volume and microarchitectural deterioration of bone tissue with porous formations being formed in the bones, leading to a decrease in the quantity of calcium in bones and a high risk of fracture for any bone, including the hip.
It is known from the prior art that a great number of preparations, which are mostly imported, are used for the prevention and treatment of osteoporosis. They can be subdivided into three broad groups:
Preparations that inhibit bone resorption:
Preparations that increase bone mass:
Agents that influence both these processes:
The preparations in these groups are widely used as sole treatment or as part of combined treatment (Ideos, Kaltsii D3 NIKOMED, Alphadol calcium, calcium carbonate, calcium citrate, etc.).
Therefore, as hundreds of preparations are currently available, it can be difficult for a medical practitioner to select an effective bone protector to treat osteoporosis. Well-placed advertisements for these preparations only make it more difficult to choose a suitable preparation. Therefore, it is important to develop methods for diagnosing osteoporosis and means of measuring the effectiveness of a preparation in treating the disease.
Laboratory, histological and radiological methods are currently used to diagnose OP and measure the effectiveness of the therapeutic activity of a preparation. A histomorphological analysis of biopsy material of the iliac crest with an assessment of osteoclast and osteoblast activity was previously considered to be the most reliable method of diagnosing OP. However, the invasive nature of these examinations limits their use. For this reason, radiological methods are currently used to diagnose OP and consequently to monitor treatment.
Standard radiography is one of the essential methods of examination. It makes it possible to carry out a morphometric analysis of vertebral bodies, identify characteristic deformities in vertebral bodies, and identify fractures in vertebral bodies with high accuracy. A standard roentgenogram is the primary and most accessible method of diagnosing osteoporosis. However, this diagnostic method relates to late diagnostic methods, as it allows specialists to detect osteoporosis only when there has been a loss of over 30-40% of bone mass. So radiography is unsuitable for early quantitative diagnosis of osteopenia, osteoporosis, and monitoring therapy.
The most accurate and informative method of examining mineral density of the bone tissue (BMD) is radiographic absorptiometry. The company “Osteometer” has developed a series of instruments for measuring BMD in the distal forearm. The DTX-100 and DTX-200 apparatuses have special software for calculating the annual loss of bone tissue, and make it possible to predict the risk of bone fractures. Modern osteometers allow us to measure BMD in various parts of the body, including the hip and vertebral bodies. All osteometers operate on two scoring scales.
The T-score indicates the number of standard deviations above or below the mean peak bone mass. The T-score decreases in parallel with the gradual decrease of bone mass with increasing age, and is used to measure BMD in adults.
The Z-score indicates the number of standard deviations above or below the mean for individuals of the same age. BMD is measured in absolute units, in standard deviations between the BMD of the patient and the age-matched mean of healthy children and adolescents of the same age and sex.
It is known from the prior art that measuring the severity of osteoporosis and the effectiveness of treatment is carried out by evaluating the results of a BMD examination, according to the classification of the WHO:
These scores are currently used for diagnosis and to measure the effectiveness of treatment with a particular preparation.
Disadvantage of the known method:
This method only takes into account the quantitative characteristic of bone mineralisation which, depending on the body mass, region, sex, and skin colour of the patient, can significantly deviate from standard values. For example, women with low body mass generally have lower BMD values than women who weigh more, particularly if they are obese, which makes it difficult to quantitatively characterise the changes caused by osteoporosis. However, it is not possible to perform an objective qualitative evaluation of the effectiveness of a preparation in treating osteoporosis on the basis of increased or decreased BMD. This is compounded by the lack of regional databases on standard regional BMD.
It is not known from the prior art, and the authors have ascertained through studies that the degree of severity of osteoporosis, changes therein and the measurement of the effectiveness of a preparation must be calculated on the basis of qualitative criteria: on the basis of the morphology of osteoporotic manifestations and specifically, the measurement of cavities in trabecular bone sections. It is difficult or impossible to determine the severity of the disease and the effectiveness of a given preparation without taking the morphometric manifestations (cavities) of osteoporosis into consideration.
The problem being addressed by the claimed invention is to objectively evaluate the effectiveness of a preparation (preparations) (bone protector) and measure cavities in trabecular bone sections. It proposes to improve the diagnostic capabilities of computerised osteometers by measuring cavities caused by osteoporosis and determine the severity of the disease not only on the basis of mineral density, but also on the basis of the presence of cavities in trabecular bone sections.
This problem is solved in that in the method of diagnosing osteoporosis, including laboratory, histological and radiological methods of examination (standard radiography) and the measurement of bone mineral density using the radiological absorptive method on osteometers, into which an additional diagnostic criterion is introduced, namely the measurement of cavities by adjusting them specially to measure cavities in trabecular bone sections using the radiological absorptive method and when diagnosing osteoporosis on osteometers, distilled water is introduced into special incubation apparatuses around the examined limb bones of the hands and feet.
A list of osteometric studies of patients observed by the authors is given below. These patients had not been diagnosed with osteoporosis based on the results of BMD measurements (see examples)
Female patient A. Decrease in BMD T-score from −2.1 to −2.3 SD. Under the WHO classification, the diagnosis would be 3 degree osteopenia. However, there is a cavity measuring 2×4 mm in the trabecular section of the ulna of the patient. This is the principal indicator of two indicators—it is a sign of osteoporosis. (see
The BMD (bone mineral density) of female patient B corresponds to 2 degree osteopenia (−1.8 SD). However, in the trabecular bone sections there are sections with significant demineralisation, which the authors refer to as “cavities”, i.e., this is osteoporosis, not osteopenia. (see
It is not known from the prior art that detecting cavities in bones or negative changes in values for bone mineral density is significant in diagnosing osteoporosis. However all modern osteometers do not “see” cavities, as they are only set to measure BMD, which is a disadvantage of such apparatuses. In order for bone cavities to be visible, it is necessary to create osteometers which comply with certain conditions. The authors have established that there must be distilled water in special incubation apparatuses around the limb bones (arm, leg) being examined. Then it is possible for osteometers such as the DTX-100 to measure BMD and cavities simultaneously. If there is air surrounding the organs being examined instead of distilled water, cavities will not be measured. The experience of the authors and new knowledge about osteoporosis shows that there is now a great need for such apparatuses, as they also measure two additional parameters: cavities and excess salt deposits in soft tissues. For other types of osteometers (such as the DTX-200), special settings are required in order for the apparatus to “see” cavities, these settings were created by the authors on the basis of the reference data recorded on a DTX-100 apparatus.
In certain situations when operating one of these “seeing” apparatuses the BMD indicators are decreased, for example to −2.4 SD (osteopenia), however when cavities are discovered in the bones of such patients, they must be diagnosed with osteoporosis. This is particularly important in cases where these cavities increase during observation or bone fractures are indicated in the medical history of the patient.
For this reason, measuring the effectiveness of a preparation for treating osteoporosis on next generation apparatuses such as the DTX-200 (which does not see cavities) on the basis of only one indicator—BMD—may be inexact.
For example, female patient F was prescribed Kaltsii D3 NIKOMED. Example 2 shows the results after 12 months of treatment. Mineralisation increased from −3.4 to −1.9 SD (from osteoporosis to degree osteopenia), but cavities increased. Thus if the effectiveness of the treatment is evaluated on a DTX 200 apparatus on the basis of BMD, this may be evaluated as a positive result, and consequently, the effectiveness of this preparation (Kaltsii D3 NIKOMED) and the possibility of withdrawing the preparation or altering its dose, reducing the duration of treatment etc.
If changes in the disease and the effectiveness of the preparation “Kaltsii D3 NIKOMED” in treating osteoporosis are measured on a DTX-100 apparatus, (or a DTX-200 with special settings, which “sees” cavities and simultaneously measures bone mineral density), the conclusion drawn from such instrument readings will be completely different—an increase in the severity of the osteoporosis, due to an increase in the dimensions of cavities, with some underlying improvement in bone mineralisation. The preparation “Kaltsii D3 NIKOMED” is not effective. The preparation must be replaced by another, because of the increase in cavities, i.e. the absence of an effect in restoring the bone tissue structure.
Female patient F. Post-menopausal osteoporosis. Cavities in metaphyseal (trabecular) bone sections, BMD T-score −3.4 SD. (see
The aim of this invention is to develop a method to improve diagnosis of osteoporosis and to objectively evaluate the effectiveness of the preparation (s) (bone protector).
The authors propose the following method:
Include a homogenous group of patients of the same age and sex in the test group and the comparison group.
1. Select patients to measure the effectiveness of the preparation: only with cavities present;
2. Patients with BMD of −2.5 SD and lower
3. Only female patients with primary osteoporosis (for example, with post-menopausal osteoporosis). Or only male patients with primary osteoporosis.
4. Exclude patients with secondary osteoporosis with various systemic endocrine diseases, oncopathologies etc.
5. Patients give their consent to participate in the experiment.
6. Patients must not know which preparation they are taking (blind test)
7. Radiological absorptive osteometry is conducted on both groups before treatment begins and every three-four months thereafter.
8. The results achieved are subject to standard statistical processing. Any preparation may be selected as a reference (control), preferably the most widely purchased.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2012115655 | Apr 2012 | RU | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/RU2012/000688 | 8/21/2012 | WO | 00 | 3/10/2015 |
